Pimecrolius on T cell Responses in Atopic March

描述（由申请人提供）：该项目的总体目标是了解特应性皮炎（AD）儿童的特应性进展和皮肤在系统过敏原致敏过程中的作用。我们的总体假设是AD导致皮肤过敏原吸收增加和全身过敏原致敏，反映在高IgE水平上。这使得阿尔茨海默病患者容易发生呼吸道过敏（特应性三月）。预防性外用吡美莫司改善皮肤屏障功能，可减少过敏原吸收、致敏，降低哮喘患病率。这可以通过吡美莫司治疗组皮肤白细胞抗原(CLA)+ TH2细胞的表达降低来证明。由诺华制药公司支持的吡美莫司临床试验“一项为期3年，随机，双盲的载体对照研究，以评估Elidel 1%乳膏改善婴儿AD病程的安全性和有效性”，为研究特应性皮炎的机制和特应性进展提供了独特的机会。我们提出的研究有三个目的，以检查特应性行军和可能的预防。第一个目的是通过过敏原特异性和总IgE检查特异性和总过敏原致敏性。第二个目标是检查这项研究的机械部分。我们将探讨皮肤归巢T细胞的频率、细胞因子的表达以及葡萄球菌超抗原对其表达的影响。在试验的第三个目的中，我们探讨吡美莫司作为一种疾病调节剂在预防哮喘中的作用。哮喘表型将通过使用β -2激动剂和呼出一氧化氮后的肺活量测定来检查。

DESCRIPTION (provided by applicant): The overall goal of this project is to understand the atopic march and the role of the skin in this process of systemic allergen sensitization in children with atopic dermatitis (AD). Our overall hypothesis is that AD results in increased skin allergen absorption and systemic allergen sensitization reflected in high IgE levels. This makes patients with AD prone to the development of respiratory allergy (Atopic March). Improving skin barrier function with prophylactic topical pimecrolimus would reduce allergen absorption, allergen sensitization and reduce the prevalence of asthma. This would be evidenced by a decreased expression of cutaneous leukocyte antigen (CLA)+ TH2 cells in the pimecrolimus treated group. The clinical trial of pimecrolimus "A 3-year, randomized, double-blind vehicle controlled study to evaluate the safety and efficacy of Elidel 1% cream in modifying the course of AD in infants" is being supported by Novartis Pharmaceutical Co. provides an unique opportunity to study the mechanism of atopic dermatitis and the atopic march. Our proposed study has three aims in examining the atopic march and possible prevention. The first aim will examine specific and total allergen sensitization by allergen-specific and total IgE. The second aim will be examining mechanistic parts of this study. We will explore the frequency of skin homing T cells, their cytokine expression and the effect of staphylococcal superantigen on their expression. In third aim of the trial, we explore the effects of pimecrolimus as a disease-modifying agent in the prevention of asthma. Asthma phenotype will be examined by spirometry per and post-beta-2-agonist and exhaled nitric oxide.